Wegovy

Novo Nordisk upgraded its 2026 revenue outlook following a stronger third quarter driven by surging demand for oral Wegovy. The Danish drugmaker captured over 50% of new US treatment starts, though non-cash write-downs weighed on operating profit.

Novo Nordisk aims to launch five new blockbuster drugs by 2030 and reach $23 billion in annual revenue by 2035, facing rising competition from Eli Lilly and generic alternatives.